Lymphoma News

More than half of patients who received a single dose of CTX110 for relapsed or refractory large B-cell lymphoma responded to therapy, according to topline data released by the agent’s manufacturer.

Patients with lymphoid malignancies who received anti-CD20 therapy within the previous year did not demonstrate antibody responses to the messenger RNA COVID-19 vaccines, according to study results published in Blood Advances.

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

ASH will honor Donna S. Neuberg, ScD, with the 2021 Exemplary Service Award at this year’s ASH Annual Meeting, scheduled for Dec. 11-14.

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel.

Common treatments for Hodgkin lymphoma, such as radiation and chemotherapy, while effective, carry significant short- and long-term risks for patients.

Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.

September is Blood Cancer Awareness Month.

Evaluation of multiple classifiers, both alone and in combination, supports the decision to focus on cell-free DNA methylation patterns to detect cancer and predict the cancer signal origin, according to a presentation at ESMO Congress 2021.

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.